Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Human Genome Sciences has reported positive interim results from a phase IIb trial of Albuferon, in combination with ribavirin, in patients with hepatitis C who are naive to interferon alpha-based treatment regimens.
Subscribe to our email newsletter
“The results suggest that Albuferon may offer comparable or improved efficacy versus Pegasys, with half the injections and the potential for less impairment of health-related quality of life,” said David Stump, executive vice president of R&D for HGS.
The interim results of the phase IIb trial showed that the treatment group receiving Albuferon 900mcg doses every two weeks achieved a higher rate of sustained virologic response at 12 weeks following completion of therapy (SVR12), and more favorable health-related quality-of-life scores, than the Pegasys treatment group.
Among treatment-adherent patients, 73% of those in the groups receiving Albuferon every two weeks achieved SVR12, versus 63% for patients receiving Pegasys once a week.
The percentage of patients achieving SVR12 in the treatment group receiving 1200mcg doses of Albuferon every four weeks was comparable to that observed in the group receiving Pegasys once a week, supporting further evaluation of Albuferon treatment with monthly administration.
A recently initiated phase III program is evaluating both 900-microgram and 1200-microgram doses in a much larger patient population. Albuferon is being developed by HGS and Novartis under an exclusive worldwide development and commercialization agreement entered into in June 2006.